Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982

Vaccine. 2025 Jan 9:47:126701. doi: 10.1016/j.vaccine.2024.126701. Online ahead of print.

¹ GSK, Tres Cantos, Spain. Electronic address: [email protected].
² UK Health Security Agency, London, United Kingdom. Electronic address: [email protected].
³ UK Health Security Agency, London, United Kingdom. Electronic address: [email protected].
⁴ GSK, Wavre, Belgium. Electronic address: [email protected].
⁵ GSK, Rixensart, Belgium.
⁶ GSK, Rixensart, Belgium. Electronic address: [email protected].
⁷ UK Health Security Agency, London, United Kingdom. Electronic address: [email protected].
⁸ UK Health Security Agency, London, United Kingdom. Electronic address: [email protected].

No abstract available

Publication types